Ligand Activation of Peroxisome Proliferator–Activated Receptor β/δ (PPARβ/δ) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression
Open Access
- 12 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 105 (2), 418-428
- https://doi.org/10.1093/toxsci/kfn142
Abstract
Peroxisome proliferator–activated receptor (PPAR) β/δ–null mice exhibit exacerbated hepatotoxicity in response to administration of carbon tetrachloride (CCl4). To determine whether ligand activation of the receptor protects against chemical toxicity in the liver, wild-type and PPARβ/δ-null mice were administered CCl4 with or without coadministration of the highly specific PPARβ/δ ligand GW0742. Biomarkers of liver toxicity, including serum alanine aminotransferase (ALT) and hepatic tumor necrosis factor (TNF) α mRNA, were significantly higher in CCl4-treated PPARβ/δ-null mice compared to wild-type mice. Hepatic expression of TNF-like weak inducer of apoptosis receptor (TWEAKr) and S100 calcium–binding protein A6 (S100A6/calcyclin), genes involved in nuclear factor kappa B signaling, was higher in the CCl4-treated PPARβ/δ-null mice compared to wild-type mice. GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl4-induced TNF-α, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARβ/δ-null mice. Expression of TNF-α was higher in PPARβ/δ-null primary hepatocytes in response to interleukin-1β treatment compared to wild-type hepatocytes, but GW0742 did not significantly modulate TNF-α expression in hepatocytes from either genotype. While PPARβ/δ-null hepatic stellate exhibited higher rates of proliferation compared to wild-type cells, GW0742 did not affect α-smooth muscle actin expression in these cells. Combined, these findings demonstrate that ligand activation of PPARβ/δ protects against chemically induced hepatotoxicity by downregulating expression of proinflammatory genes. Hepatocytes and hepatic stellate cells do not appear to directly mediate the inhibitory effects of ligand activation of PPARβ/δ in liver, suggesting the involvement of paracrine and autocrine events mediated by hepatic cells.Keywords
This publication has 100 references indexed in Scilit:
- Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in miceBiochemical and Biophysical Research Communications, 2008
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin ResistanceCell Metabolism, 2008
- Adipocyte-Derived Th2 Cytokines and Myeloid PPARδ Regulate Macrophage Polarization and Insulin SensitivityCell Metabolism, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell linesToxicology, 2008
- Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in miceHepatology, 2007
- Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient miceThe EMBO Journal, 2007
- Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytesCellular Signalling, 2007
- Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progressionProceedings of the National Academy of Sciences of the United States of America, 2006
- PPARβ/δ selectively induces differentiation and inhibits cell proliferationCell Death & Differentiation, 2005